Inventor
TAO PEI
Inventor
US
Overview
Patents· 24 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C12Nprimary
C12NMicroorganisms or enzymes29%
A61KPreparations for medical, dental or toiletry purposes24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
C07HSugars8%
C12YEnzymes6%
C07KPeptides4%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%
G01NInvestigating or analysing materials by determining their chemical or physical properties2%
Y02ATechnologies for adaptation to climate change2%
PatentTitleYear
12,582,668Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)202612,551,569RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use202612,503,696RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of use202512,442,002RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use202512,441,7565'-cyclo-phosphonate modified nucleotides202512,378,558RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use202512,365,899RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)202512,173,086Alpha-v beta-6 integrin ligands and uses thereof202412,116,573Targeting ligands for therapeutic compounds202412,110,492RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use202412,054,718RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use202411,912,997RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use202411,884,920Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use202411,845,937RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use202311,629,349RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use202311,590,156RNAi agents for hepatitis B virus infection202311,549,112RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use202311,517,584RNAi agents for Hepatitis B virus infection202211,492,624RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1202211,214,801RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)202211,214,802RNAi agents for inhibiting expression of alpha-ENaC and methods of use202211,203,756Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use202111,180,529Alpha-v beta-6 integrin ligands and uses thereof202111,174,481Targeting ligands2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to ARROWHEAD PHARMACEUTICALS INC (24)· patent assignee history
2021–2026Based in US· patent location history
2022Patents assigned to ARROWHEADS PHARMACEUTICALS INC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS INC | 24 | 2021–2026 |
| ARROWHEADS PHARMACEUTICALS INC | 1 | 2022 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 24 | 2021–2026 |